BioSpace News Archive

Altimmune, Inc. today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral and a poster presentation on pemvidutide, the Company’s novel, investigational GLP-1/Glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease (NAFLD).

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, gives notice of the Extraordinary General Meeting of shareholders to be held on Friday, January 28, 2022.

Evotec SE MDAX/TecDAX, ISIN: DE0005664809 announced that the Company has been selected by the German Federal Ministry of Education and Research to receive a grant for the development of EVT075, a potential first-in-class immunomodulatory therapy against COVID-19.

Biosion, Inc., a global clinical stage biotechnology company, announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development, where he will lead corporate strategy, China BD, and capital fundraising.

Oncorus, Inc. today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference.

C4 Therapeutics, Inc. today announced that the Company will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST.

Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience.

Clinical Laserthermia Systems AB today announced it has promoted Mr. Michael Magnani to president of its U.S subsidiary Clinical Laserthermia Systems Americas Inc. (CLS Americas).

Faron Pharmaceuticals Ltd, a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, is pleased to announce the appointment of Marie-Louise Fjällskog, M.D., Ph.D., as Chief Medical Officer of the Company.

As of January 3, 2022, Biotage is included in Nasdaq Stockholm’s Large Cap segment.